Af­ter roller-coast­er week, CRL forces a reck­on­ing on Or­p­hazyme in­vestors — in­flat­ed shares plum­met

The meme stock par­ty is over for Or­p­hazyme.

Af­ter a week of fren­zied trad­ing — where its shares sky­rock­et­ed, at one point, more than 1000% for no ap­par­ent rea­son — the Copen­hagen-based biotech dis­closed ear­ly Fri­day that the FDA has re­ject­ed its lead drug as a treat­ment for Nie­mann-Pick dis­ease type C, ask­ing for more da­ta.

Shares $ORPH plum­met­ed 56.39% to $6.35 — and it will like­ly face an up­hill bat­tle find­ing its way back up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER